Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
(RELIEF-DPN 1 Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called LX9211 in different doses to see if it can reduce pain in people with nerve damage caused by diabetes over a few months.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use opioid medications for DPNP within 2 months before the screening or NSAIDs less than 2 weeks before the screening.
Research Team
Suma Gopinathan, PhD
Principal Investigator
Lexicon Pharmaceuticals
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a low or high dose of LX9211 or placebo once daily
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LX9211
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lexicon Pharmaceuticals
Lead Sponsor
Dr. Mike Exton
Lexicon Pharmaceuticals
Chief Executive Officer
PhD in Neuroscience from the University of Newcastle and PhD in Immunology from the University of Essen, Germany
Dr. Craig Granowitz
Lexicon Pharmaceuticals
Chief Medical Officer since 2021
MD